Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies.

Current atherosclerosis reports - 25 Sept 2017

Messas Nathan, Dubé Marie-Pierre, Tardif Jean-Claude

Abstract excerpt

PURPOSE OF REVIEW: High-density lipoproteins (HDL) are involved in reverse cholesterol transport. Results from randomized trials of HDL-targeting therapies, including cholesteryl ester transfer protein (CETP) inhibitors, have shown a lack of benefit in unsegmented populations. These observations could be explained by inter-individual variability of clinical responses to such agents depending on the patients'...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Cholesterol, HDL

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Genotype

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hypolipidemic Agents

Share to Lipoproteins, HDL

Share to Pharmacogenetics

Source

Identifiers

PMID: 28944433
DOI: 10.1007/s11883-017-0679-5

Genes

CETP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies.PMID 28944433Read ↗

Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for DyslipidemiaSemantic proximity Read ↗

APOE genotype and the effect of statins on lipid outcomes: A meta-analysis.Semantic proximity Read ↗

APOE genotype and the effect of statins: a systematic review and meta-analysisSemantic proximity Read ↗

Genetic contribution to lipid target achievement with statin therapy: a prospective study.Semantic proximity Read ↗

Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart DiseaseSemantic proximity Read ↗

When the same treatment has different response: The role of pharmacogenomics in statin therapySemantic proximity Read ↗

Genetic determinants of response to statins.Semantic proximity Read ↗

Genetics and personalized medicine--a role in statin therapy?Semantic proximity Read ↗

Cholesteryl ester transfer protein polymorphisms, statin use, and their impact on cholesterol levels and cardiovascular events.Semantic proximity Read ↗

Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review.Semantic proximity Read ↗

Pharmacogenomics of cholesterol-lowering therapy.Semantic proximity Read ↗

Meta-analysis of genome-wide association studies of HDL cholesterol response to statins.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.